AstraZeneca Will Take Over mGluR Program From NPS Pharmaceuticals For $30 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
NPS says it will use the money to fund further development of late-stage candidates Preos and Gattex.
You may also be interested in...
Pfizer And Taisho Reach Deal for Schizophrenia Candidate
Pfizer joins Merck and AstraZeneca in pursuing metabotropic glutamate receptor agonist candidates.
Pfizer And Taisho Reach Deal for Schizophrenia Candidate
Pfizer joins Merck and AstraZeneca in pursuing metabotropic glutamate receptor agonist candidates.
Merck, Addex Parkinson’s Venture To Develop Treatments That Target Glutamate Receptor
Firms ink $170 million-plus deal for positive allosteric modulators targeting metabotropic glutamate receptor 4 in Parkinson’s disease and other indications.